Fig. 6: The mechanism of interaction between TADs and MED15.
From: The mechanism of YAP/TAZ transactivation and dual targeting for cancer therapy
a HDX-MS characterization for identification of YAP-MED15 binding sites. Deuterium uptake plots of MED15 peptides (Region I: AA 492-511, +4 charge; Region II: AA 531-551, +5 charge) and YAP peptide (AA 491-502, +3) were measured in the presence and absence of their binding partners. Data are plotted as percent deuterium uptake versus time (logarithmic scale). Red and green plots represent the unbound and bound states, respectively (n = 3 technical replicates). b NMR structure ensemble of MED15-ABD3 consisting of 20 lowest-energy models. c Analysis for the CSP of 15N-YAP-TAD upon titration with ABD3. d The residues with significant CSP during NMR titration in (c) are mapped on the YAP-TAD structure in red. e Predicted helix formation propensity for YAP-TAD with or without ABD3 using TALOS-N webserver. f Analysis for the change in CSP of 15N-ABD3 upon titration with YAP-TAD. g The residues with significant CSP change during NMR titration in (f) are mapped on the MED15-ABD3 structure in blue. h Analysis for the change in CSP of 15N-ABD3 upon titration with the pentapeptide FLTWL. i The residues with significant CSP change in (h) during NMR titration experiment are mapped on the MED15-ABD3 structure in blue. Data are presented as mean ± SD.
